Summary & Overview
HCPCS J1303: Injection of ravulizumab-cwvz, 10 mg
HCPCS Level II code J1303 denotes an injection of ravulizumab-cwvz, 10 mg, a long-acting monoclonal antibody used in specialty medicine. Nationally, accurate coding for high-cost injectable biologics like ravulizumab is important for claim adjudication, benefit design, and utilization management across commercial and public payers. Covered payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of what J1303 represents clinically and operationally, plus what to expect when billing for an injected biologic therapy in outpatient infusion settings and physician offices. The publication highlights payer coverage patterns, reimbursement benchmarks, and relevant policy considerations affecting specialty drug administration. Clinical context covers the service type and typical sites of service where this injectable is administered. Where input data is unavailable, the report notes those gaps so readers can identify areas requiring payer-specific verification.
Billing Code Overview
HCPCS Level II code J1303 represents an injection of ravulizumab-cwvz, 10 mg. This billing code describes administration of a monoclonal antibody therapy delivered by injection.
-
Service type: Injectable biologic therapy
-
Typical site of service: Infusion clinic, outpatient hospital, or physician office
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 38-year-old patient with paroxysmal nocturnal hemoglobinuria (PNH) presents to an outpatient infusion center for scheduled maintenance therapy. The patient receives J1303 (injection, ravulizumab-cwvz, 10 mg) as an intravenous infusion following preset weight-based dosing and the manufacturer’s reconstitution instructions. Pre-infusion nursing assessment includes vital signs, verification of informed consent, review of prior infusion reactions, and confirmation of concomitant vaccinations (meningococcal) and prophylactic antibiotics as indicated. A supervising hematologist orders the dose in the electronic medical record; an advanced practice provider performs medication reconciliation and documents indication. The infusion is administered by an infusion nurse in a hospital outpatient infusion room or freestanding infusion center; post-infusion monitoring for hypersensitivity or infusion reactions occurs for 30–60 minutes depending on prior tolerance. Documentation includes the supplied drug name and NDC, lot number, dose administered, route, site of service, any modifiers for billing, start and stop times, and any adverse events. Billing uses HCPCS code J1303 with applicable modifiers and the primary diagnosis code reflecting PNH or other approved indications.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier |